Oxford, UK – 13 April 2012. OGT, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released a major new update to its CytoSure® Interpret Software for array Comparative Genomic Hybridisation (aCGH) analysis. By utilising an entirely new relational database design, the software now allows sample data to be stored and analysed in accordance to its relationship with other data. For example, samples can be segregated into different projects by sample type or by user, thereby simplifying analysis. It can also perform common analysis steps automatically via the “Accelerate Workflow” mode, which significantly speeds up analysis, especially when working with a large number of samples. The intuitive graphical interface detects DNA regions exhibiting genomic variation, with results presented in an easy-to-use report, annotated with the relevant syndromes, genes, exons, and segmental duplications. This also includes links to external databases, putting each variation in context and helping to highlight the biological implications of the data generated. In addition, this latest software release incorporates a number of cancer annotation tracks, enabling meaningful interpretation of results obtained using OGT’s growing portfolio of CytoSure Cancer arrays.
Dr. Agne Liedén from the Department of Molecular Medicine and Surgery at the Karolinska Institutet, who has recently integrated the new CytoSure Interpret Software into his laboratory’s workflow, commented: “I have been extremely impressed with the ease-of-use and flexibility of the software. In our experience, OGT is very responsive to customer feedback and has produced an excellent software package.” OGT’s CEO, Dr Mike Evans, said: “The new update is part of OGT’s overall strategy, which is dedicated to providing products and services that convert complex datasets into easily interpretable, meaningful results. Our aim is to allow researchers to focus all of their time and energy on investigating the biology, rather than sifting through their data. In this case, constant innovation ensures that our CytoSure Interpret Software remains the industry-leading aCGH analysis software, and our dedicated software development team are continually implementing enhanced features and capabilities in response to customer feedback and new developments in the field.”
To complement OGT’s growing range of proprietary arrays containing both CNV and SNP probes, CytoSure Interpret Software can identify DNA regions exhibiting copy number variation, loss of heterozygosity and mosaicism. The latest update also provides a unique ‘Family Tree’ view, which makes it easy to examine inheritance patterns in up to three generations of the same family. In addition, to further ensure reliable, consistent results, the latest version of CytoSure Interpret Software incorporates permission-based account management. This allows individual users to be assigned specific, customisable access to system functionality and delivers a comprehensive audit trail of any workflow changes, thereby providing consistency of analysis and reporting.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read